Anavex Receives Approval to Commence Phase I Clinical Trial in Alzheimer’s Disease

Anavex Appoints Dr. Jeffrey Cummings to its Scientific Advisory Board

Anavex Appoints Independent Director

Anavex Appoints Dr. Rachelle Doody to Scientific Advisory Board

Anavex Adds Dr. Paul Aisen to Scientific Advisory Board

Anavex Comments on President Obama’s Signing of National Alzheimer’s Project Act into Law

Alzheimer’s Weekly Names ANAVEX 2-73 the Number One Most Promising Trial Drug in Alzheimer’s Disease and Anavex’s Phase I Clinical Program as “Trial of the Year”

Anavex Files Phase I Regulatory Submission for ANAVEX 2-73 in Alzheimer’s Disease

Anavex Appoints David Tousley as CFO

ANAVEX 2-73: Journal of Psychopharmacology Publishes Anti-Amnesic and Neuroprotective Data Against Amyloid Toxicity For First of a New Class in Alzheimer’s Disease